Aurobindo Pharma has received final approval from the US Food and Drug Administration to manufacture and market its generic Naproxen Sodium tablets, used for treating osteoporosis in postmenopausal women. The company said the drug has an estimated market size of $96 million for the twelve months ended January 2016 and expects to launch it in the next fiscal's first quarter.